Serotonin (5-HT) action via the 5-HT 2C receptor (5-HT 2C R) provides an important modulatory influence over neurons of the prefrontal cortex (PFC), which is critically involved in disorders of executive function including substance use disorders. In the present study, we investigated the distribution of the 5-HT 2C R in the rat prelimbic PFC (PrL), a subregion of the medial PFC (mPFC), using a polyclonal antibody raised against the 5-HT 2C R. The expression of 5-HT 2C R immunoreactivity (IR) was highest in the deep layers (layerV/VI) of the mPFC. The 5-HT 2C R-IR was typically most intense at the periphery of cell bodies and the initial segment of cell processes. Approximately 50% of the 5-HT 2C R-IR detected was found in GAD 67-positive neurons. Of the subtypes of γ-aminobutyric acid (GABA) interneurons identified by expression of several calcium-binding proteins, a significantly higher percentage of neurons expressing IR for parvalbumin also expressed 5-HT 2C R-IR than did the percentage of neurons expressing calbindin-IR or calretinin-IR that also expressed 5-HT 2C R-IR. Since parvalbumin is located in basket and chandelier GABA interneurons which project to cell body and initial axon segments of pyramidal cells, respectively, these results raise the possibility that the 5-HT 2C R in the mPFC acts via the parvalbumin-positive GABAergic interneurons to regulate the output of pyramidal cells in the rat mPFC.
KeywordsImmunohistochemistry; parvalbumin; calbindin; calretinin; prelimbic prefrontal cortex Recent advances in understanding the neural circuitry and mechanisms underlying the vulnerability to drug abuse, the progression of drug use to addiction, and the triggers for relapse provide hope that new therapeutic approaches are forthcoming for this brain disorder (Kalivas and Volkow, 2005;Koob and Le, 2005;Hyman et al., 2006). A loss of the normal regulatory role for prefrontal cortex (PFC) over the mesoaccumbens dopamine (DA) circuit that is central to drug reward has been identified as a key component in addiction, and pharmacological approaches to reinstate normal PFC function may prove to be Address for Correspondence: Kathryn A. Cunningham, Ph.D., Center for Addiction Research, Department of Pharmacology and Toxicology, University of Texas Medical Branch at Galveston, 301 University Blvd, Galveston, TX 77555-1031, Voice: 409-772-9629, FAX: 409-772-9642, kcunning@utmb.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author ManuscriptNeuroscience. Author manuscript; available in PMC 2010 August 2. (Kalivas and Volkow, 2005). The PFC i...